EFTISARC-NEO Trial: Pembrolizumab + Eftilagimod Neoadjuvant STS 2024

Phase II trial evaluating the safety and efficacy of pembrolizumab combined with eftilagimod alpha (LAG-3 agonist) and radiotherapy as neoadjuvant treatment for high-grade soft tissue sarcomas. The study assesses tumor pathologic response, measured by hyalinization, and explores changes in the tumor microenvironment and immune infiltrates. Funded by the Medical Research Agency in Poland.